Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

We report the identification of three structurally diverse compounds – compound 4, GC376, and MAC-5576 – as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.

Article activity feed

  1. SciScore for 10.1101/2020.08.03.235291: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    BlindingCells were incubated at 37 °C under 5% CO2 for 72 h and then viral cytopathic effect was scored in a blinded manner.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line AuthenticationContamination: Cells were confirmed as mycoplasma negative prior to use.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Measurement of cellular cytotoxicity: Vero-E6 cells were incubated with the compound of interest for 48 h at 37 °C under 5% CO2 and then cellular cytotoxicity was determined with the XTT Cell Proliferation Assay Kit (ATCC) according to the manufacturer’s instructions.
    Vero-E6
    suggested: None
    Software and Algorithms
    SentencesResources
    IC50 values were determined by fitting an asymmetric sigmoidal curve to the data (GraphPad Prism).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)
    The mapping of electrostatic potential surfaces was generated in PyMOL with the APBS plug-in19.
    PyMOL
    suggested: (PyMOL, RRID:SCR_000305)

    Results from OddPub: Thank you for sharing your data.


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.